Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **subgenual anterior cingulate cortex** (**sgACC**) is a distinct anatomical subdivision of the anterior cingulate cortex located beneath the genu of the corpus callosum. It corresponds primarily to Brodmann area 25 but also includes ventral portions of areas 24 and 32[1][6]. The sgACC is part of the limbic system and serves as a critical hub for fronto-limbic networks involved in emotional processing and mood regulation[8]. It has extensive connections with other emotion-related brain regions such as the amygdala, periaqueductal gray, thalamus, hypothalamus, hippocampus, and orbitofrontal cortex[1][7]. Functionally, the sgACC regulates autonomic states through projections to brainstem nuclei involved in visceral control. It plays an essential role in expressing negative emotional states and regulating endocrine responses to stressors. Structural or functional abnormalities within this region are strongly implicated in major depressive disorder—especially treatment-resistant forms—and bipolar disorder. Hyperactivity or altered connectivity involving the sgACC is associated with negative affectivity; normalization often accompanies successful antidepressant treatment including pharmacotherapy, cognitive-behavioral therapy (CBT), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or deep brain stimulation targeting this region[2][5]. The **sgACC is not a molecular target** such as a receptor or enzyme but rather an anatomically defined cortical region that can be modulated by neuromodulation therapies. Therefore it does not have interacting drugs or mechanisms typical for molecular targets. There are no direct drug interactions at the molecular level; instead interventions like deep brain stimulation aim to modulate its activity electrically for therapeutic benefit in severe mood disorders. Safety concerns relate mainly to risks inherent in invasive neuromodulation procedures rather than pharmacology. In summary: The subgenual anterior cingulate cortex is an important *brain region*—not a molecule/receptor/therapeutic target per se—but it serves as an anatomical focus for neuromodulatory treatments due to its central role in mood regulation circuitry implicated across several psychiatric diseases[2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Subgenual anterior cingulate cortex (sgACC).